FDA Grants Priority Review for Madrigal Pharma’s Non-Alcoholic Steatohepatitis (NASH) Treatment
Madrigal Pharmaceuticals, a leading clinical-stage biopharmaceutical company dedicated to advancing innovative treatments for nonalcoholic steatohepatitis (NASH), has exciting news to share. The U.S. ...
SpringWorks Therapeutics’ Nirogacestat Granted Priority Review by FDA for Desmoid Tumor Treatment
SpringWorks Therapeutics, a clinical-stage biopharmaceutical company, has received acceptance from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for nirogacestat, an i ...